FMR LLC boosted its stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 1.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 655,851 shares of the company’s stock after buying an additional 10,562 shares during the period. FMR LLC owned approximately 1.66% of Taro Pharmaceutical Industries worth $75,875,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its holdings in Taro Pharmaceutical Industries by 8.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 260,672 shares of the company’s stock valued at $25,739,000 after buying an additional 20,407 shares during the period. Acadian Asset Management LLC raised its holdings in Taro Pharmaceutical Industries by 136.8% in the 2nd quarter. Acadian Asset Management LLC now owns 235,930 shares of the company’s stock valued at $27,295,000 after buying an additional 136,287 shares during the period. Freestone Capital Holdings LLC raised its holdings in Taro Pharmaceutical Industries by 14.7% in the 1st quarter. Freestone Capital Holdings LLC now owns 166,748 shares of the company’s stock valued at $16,464,000 after buying an additional 21,392 shares during the period. Millennium Management LLC raised its holdings in Taro Pharmaceutical Industries by 2.7% in the 1st quarter. Millennium Management LLC now owns 104,861 shares of the company’s stock valued at $10,354,000 after buying an additional 2,787 shares during the period. Finally, Alps Advisors Inc. raised its holdings in Taro Pharmaceutical Industries by 7.7% in the 2nd quarter. Alps Advisors Inc. now owns 57,924 shares of the company’s stock valued at $6,701,000 after buying an additional 4,138 shares during the period. Hedge funds and other institutional investors own 10.40% of the company’s stock.
Several equities analysts have weighed in on TARO shares. Zacks Investment Research downgraded Taro Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 16th. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 target price on shares of Taro Pharmaceutical Industries in a research report on Friday, August 10th. Finally, ValuEngine downgraded Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research report on Monday, September 24th.
Taro Pharmaceutical Industries (NYSE:TARO) last released its earnings results on Thursday, August 9th. The company reported $1.71 earnings per share for the quarter, missing the consensus estimate of $2.33 by ($0.62). The firm had revenue of $154.62 million during the quarter, compared to analyst estimates of $179.54 million. Taro Pharmaceutical Industries had a net margin of 34.18% and a return on equity of 11.73%. On average, sell-side analysts anticipate that Taro Pharmaceutical Industries Ltd. will post 7.65 EPS for the current fiscal year.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Recommended Story: Market Capitalization
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.